Cantor Fitzgerald Estimates BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Bicara Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings per share of ($1.98) for the year. Cantor Fitzgerald has a “Overweight” rating and a $13.01 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

BCAX has been the topic of several other research reports. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target on the stock in a research report on Friday, May 23rd. Wall Street Zen downgraded shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Friday, May 23rd. Finally, Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.86.

Bicara Therapeutics Stock Performance

BCAX stock opened at $12.58 on Tuesday. The firm’s fifty day moving average is $12.30 and its 200 day moving average is $14.03. Bicara Therapeutics has a one year low of $7.80 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28).

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth about $25,000. Spire Wealth Management purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth about $31,000. BNP Paribas Financial Markets purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth about $32,000. Legal & General Group Plc purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth about $33,000. Finally, Summit Investment Advisors Inc. purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth about $35,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.